



March 31, 2022

Subject: Unit of Sale NDC and Product Number Change for **Enoxaparin Sodium Injection, USP**

Dear Customer,

Fresenius Kabi currently markets **Enoxaparin Sodium Injection, USP** with the Unit of Sale NDC numbers and product numbers listed as "current" in the table below. We are in the process of transitioning to new NDC numbers and product numbers, which is detailed below in the columns titled "Future," along with estimated transition timing.

Enoxaparin Sodium Injection, USP Prefilled Syringes*					
Product Description	Product Number		Unit of Sale NDC		Estimated Transition Timing in 2022
	Current	Future	Current	Future	
30 mg per 0.3 mL	FK553383	551993	63323-533-83	63323-559-93	June
40 mg per 0.4 mL	FK553587	556497	63323-535-87	63323-564-97	May
60 mg per 0.6 mL	FK560788	556698	63323-607-88	63323-566-98	September
80 mg per 0.8 mL	FK553190	558499	63323-531-90	63323-584-99	May
100 mg per 1 mL	FK560584	558696	63323-605-84	63323-586-96	August
120 mg per 0.8 mL	FK560990	556099	63323-609-90	63323-655-99	September
150 mg per 1 mL	FK553784	558994	63323-537-84	63323-589-94	June

*300 mg per 3 mL will not be transitioning to new NDC

For product availability updates, please visit our web site [at www.fresenius-kabi.com/us/pharmaceutical-product-availability](http://www.fresenius-kabi.com/us/pharmaceutical-product-availability), call our Customer Service team at 1-888-386-1300, or contact your wholesaler.

For clinical questions, please contact Fresenius Kabi USA Medical Affairs at 1-800-551-7176, Monday-Friday between 8 a.m. and 5 p.m. (CST) or email medinfo.USA@fresenius-kabi.com.

Sincerely,

Sarala Bindu
Marketing Manager